#METABOLOMICS WORKBENCH blfitz_20200528_092932_mwtab.txt DATATRACK_ID:2025 STUDY_ID:ST001391 ANALYSIS_ID:AN002320 PROJECT_ID:PR000954
VERSION             	1
CREATED_ON             	May 28, 2020, 4:23 pm
#PROJECT
PR:PROJECT_TITLE                 	Metabolic Response in Patients with Post-Treatment Lyme Disease
PR:PROJECT_TITLE                 	Symptoms/Syndrome
PR:PROJECT_SUMMARY               	Sera from two small cohorts of patients were analyzed by untargeted liquid
PR:PROJECT_SUMMARY               	chromatography-mass spectrometry (LC-MS) to identify small molecule metabolites
PR:PROJECT_SUMMARY               	and metabolic pathways that differ between PTLDS and clinically cured
PR:PROJECT_SUMMARY               	(non-PTLDS) patients at baseline, following treatment completion and at one-year
PR:PROJECT_SUMMARY               	post-treatment.
PR:INSTITUTE                     	Colorado State University
PR:LAST_NAME                     	Belisle
PR:FIRST_NAME                    	John
PR:ADDRESS                       	200 West Lake, Campus Delivery 0922, Colorado State University, Fort Collins,
PR:ADDRESS                       	CO, 80523, USA
PR:EMAIL                         	john.belisle@colostate.edu
PR:PHONE                         	9704915384
#STUDY
ST:STUDY_TITLE                   	Metabolic Response in Patients with Post-Treatment Lyme Disease
ST:STUDY_TITLE                   	Symptoms/Syndrome
ST:STUDY_SUMMARY                 	Post-treatment Lyme Disease Symptoms/Syndrome (PTLDS) occurs in approximately
ST:STUDY_SUMMARY                 	10% of Lyme disease patients following antibiotic treatment. Objective
ST:STUDY_SUMMARY                 	biomarkers or specific clinical symptoms to identify PTLDS patients do not
ST:STUDY_SUMMARY                 	currently exist and the PTLDS classification is based on the report of
ST:STUDY_SUMMARY                 	persistent subjective symptoms for ≥ 6 months following antibiotic treatment
ST:STUDY_SUMMARY                 	for Lyme disease. Untargeted liquid chromatography-mass spectrometry
ST:STUDY_SUMMARY                 	metabolomics was used to define metabolic changes that occurred longitudinally
ST:STUDY_SUMMARY                 	in PTLDS and clinically cured non-PTLDS Lyme patients from two separate cohorts.
ST:STUDY_SUMMARY                 	An elastic net regularization model was applied to define the metabolites that
ST:STUDY_SUMMARY                 	classified PTLDS and non-PTLDS patients at different time points, and the PTLDS
ST:STUDY_SUMMARY                 	defining metabolites were evaluated in two sample cohorts using linear
ST:STUDY_SUMMARY                 	discriminant analysis. This study determined that observable metabolic
ST:STUDY_SUMMARY                 	alterations occur between PTLDS and non-PTLDS patients at multiple time points.
ST:STUDY_SUMMARY                 	These metabolic alterations discriminated between PTLDS and non-PTLDS patients
ST:STUDY_SUMMARY                 	and consisted of metabolites of glycerophospholipid, bile acid and acylcarnitine
ST:STUDY_SUMMARY                 	metabolism. Longitudinal analyses showed distinct patterns in metabolite
ST:STUDY_SUMMARY                 	abundance changes that indicated a greater variability in PTLDS vs non-PTLDS
ST:STUDY_SUMMARY                 	patients. These data provide evidence that an objective metabolite-based
ST:STUDY_SUMMARY                 	measurement can distinguish patients with PTLDS and help understand the
ST:STUDY_SUMMARY                 	underlying biochemistry of PTLDS.
ST:INSTITUTE                     	Colorado State University
ST:DEPARTMENT                    	MIP
ST:LABORATORY                    	Belisle
ST:LAST_NAME                     	Belisle
ST:FIRST_NAME                    	John
ST:ADDRESS                       	200 West Lake, Campus Delivery 0922, Colorado State University, Fort Collins,
ST:ADDRESS                       	CO, 80523
ST:EMAIL                         	john.belisle@colostate.edu
ST:PHONE                         	9704915384
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
#FACTORS
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_10B	Time point:Baseline | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=40-49; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_10OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=40-49; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_10PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=40-49; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_11B	Time point:Baseline | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_11OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_11PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_12B	Time point:Baseline | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=20-29; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_12OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=20-29; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_12PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=20-29; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_13B	Time point:Baseline | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_13OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_13PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_14B	Time point:Baseline | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_14OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_14PT	Time point:Post-treatment | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_15B	Time point:Baseline | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_15OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_15PT	Time point:Post-treatment | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_16B	Time point:Baseline | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_16OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_16PT	Time point:Post-treatment | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_17B	Time point:Baseline | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=20-29; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_17OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=20-29; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_17PT	Time point:Post-treatment | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=20-29; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_18B	Time point:Baseline | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=30-39; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_18OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=30-39; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_18PT	Time point:Post-treatment | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=30-39; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_19B	Time point:Baseline | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=70-79; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_19OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=70-79; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_19PT	Time point:Post-treatment | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=70-79; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_1B	Time point:Baseline | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_1OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_1PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_20B	Time point:Baseline | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_20OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_20PT	Time point:Post-treatment | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_21B	Time point:Baseline | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_21OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_21PT	Time point:Post-treatment | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_22B	Time point:Baseline | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=30-39; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_22OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=30-39; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_22PT	Time point:Post-treatment | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=30-39; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_23B	Time point:Baseline | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_23OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_23PT	Time point:Post-treatment | PTLDS:No	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_24B	Time point:Baseline | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_24OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_24PT	Time point:Post-treatment | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_25B	Time point:Baseline | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=60-69; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_25OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=60-69; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_25PT	Time point:Post-treatment | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=60-69; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_26B	Time point:Baseline | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_26OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_26PT	Time point:Post-treatment | PTLDS:No	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_2B	Time point:Baseline | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=20-29; Gender=F; Race="Nonwhite, black or hispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Equ; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_2PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=20-29; Gender=F; Race="Nonwhite, black or hispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_3B	Time point:Baseline | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=70-79; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_3OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=70-79; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_3PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=70-79; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Neg; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_4B	Time point:Baseline | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_4OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_4PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_5B	Time point:Baseline | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=30-39; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_5OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=30-39; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_5PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=30-39; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_6B	Time point:Baseline | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_6OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_6PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early disseminated Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_7PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=20-29; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_8B	Time point:Baseline | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=20-29; Gender=F; Race="Black, Hispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_8OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=20-29; Gender=F; Race="Black, Hispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_8PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=20-29; Gender=F; Race="Black, Hispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Equ; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_9B	Time point:Baseline | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_9OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=NA; Lyme EIA/ELISA Result=NA; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_JHU_9PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=JHU; Sample Type=Early localized Lyme; Cohort=2; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Vls-E-1/PepC10 (QUEST); Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_10B	Time point:Baseline | PTLDS:No	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=40-49; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_10OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=40-49; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_10PT	Time point:Post-treatment | PTLDS:No	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=40-49; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_11B	Time point:Baseline | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=70-79; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_11OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=70-79; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_11PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=70-79; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_12B	Time point:Baseline | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_12OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_12PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_13B	Time point:Baseline | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=30-39; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_13PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=30-39; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_14B	Time point:Baseline | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=40-49; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_14OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=40-49; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_14PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=40-49; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_15B	Time point:Baseline | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_15OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_15PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_17B	Time point:Baseline | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_17OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_17PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_18B	Time point:Baseline | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=60-69; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_18OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=60-69; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_18PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=60-69; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_19B	Time point:Baseline | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=30-39; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_19OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=30-39; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_19PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=30-39; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_1B	Time point:Baseline | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_1OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_1PT	Time point:Post-treatment | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_20B	Time point:Baseline | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_20OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_20PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_21B	Time point:Baseline | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=30-39; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_21OYFU	Time point:One-year follow-up | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=30-39; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_21PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=30-39; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_22B	Time point:Baseline | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=30-39; Gender=F; Race=Asian; Lyme EIA/ELISA Method=C6; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_22PT	Time point:Post-treatment | PTLDS:Yes	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=30-39; Gender=F; Race=Asian; Lyme EIA/ELISA Method=C6; Lyme EIA/ELISA Result=pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_2B	Time point:Baseline | PTLDS:No	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=40-49; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_2OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=40-49; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_2PT	Time point:Post-treatment | PTLDS:No	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=40-49; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_3B	Time point:Baseline | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_3OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_3PT	Time point:Post-treatment | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_4B	Time point:Baseline | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=60-69; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_4OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=60-69; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_4PT	Time point:Post-treatment | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=60-69; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_5B	Time point:Baseline | PTLDS:No	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=pos; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_5OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_5PT	Time point:Post-treatment | PTLDS:No	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=50-59; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_6B	Time point:Baseline | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=20-29; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_6OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=20-29; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_6PT	Time point:Post-treatment | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=20-29; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_7B	Time point:Baseline | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Neg; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_7OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_7PT	Time point:Post-treatment | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=50-59; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_8B	Time point:Baseline | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=60-69; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_8OYFU	Time point:One-year follow-up | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=60-69; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=NA; Lyme IgG=NA
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_8PT	Time point:Post-treatment | PTLDS:No	Sample Provider=NYMC; Sample Type=Early localized Lyme; Cohort=1; Age=60-69; Gender=F; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Neg; Lyme IgM=Pos; Lyme IgG=Pos
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_9B	Time point:Baseline | PTLDS:No	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Neg
SUBJECT_SAMPLE_FACTORS           	-	PTLDS_NYMC_9PT	Time point:Post-treatment | PTLDS:No	Sample Provider=NYMC; Sample Type=Early disseminated Lyme; Cohort=1; Age=40-49; Gender=M; Race="White, NonHispanic"; Lyme EIA/ELISA Method=Wampole; Lyme EIA/ELISA Result=Pos; Lyme IgM=Pos; Lyme IgG=Pos
#COLLECTION
CO:COLLECTION_SUMMARY            	Sera (both cohorts) were collected at the time of diagnosis (baseline); at the
CO:COLLECTION_SUMMARY            	completion of antibiotic therapy, approximately two to three weeks following
CO:COLLECTION_SUMMARY            	diagnosis (post-treatment); and at one-year post-treatment (one-year follow-up).
CO:COLLECTION_SUMMARY            	PTLDS (symptoms) patients were classified as such if symptoms developed at or
CO:COLLECTION_SUMMARY            	within 6 months following diagnosis and persisted for at least 6 months
CO:COLLECTION_SUMMARY            	following the completion of antibiotic therapy. Patients were classified as
CO:COLLECTION_SUMMARY            	PTLDS (syndrome) if they met the above criteria and with daily life functional
CO:COLLECTION_SUMMARY            	impairment reported.
CO:SAMPLE_TYPE                   	Blood (serum)
#TREATMENT
TR:TREATMENT_SUMMARY             	N/A
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Serum samples were randomized prior to extraction of small molecule metabolites
SP:SAMPLEPREP_SUMMARY            	and LC-MS analyses. Metabolites were extracted with 75% methanol as previously
SP:SAMPLEPREP_SUMMARY            	described. Extracted metabolites were analyzed by LC-MS.
SP:SAMPLEPREP_PROTOCOL_COMMENTS  	doi:10.1038/nprot.2011.335
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Agilent 6520
CH:COLUMN_NAME                   	Poroshell 120 EC-C8 (100 x 2.1mm, 2.5um)
CH:FLOW_GRADIENT                 	2-98% non-linear gradient
CH:FLOW_RATE                     	0.25 ml/min
CH:COLUMN_TEMPERATURE            	50
CH:SOLVENT_A                     	water, 0.1% formic acid
CH:SOLVENT_B                     	acetonitrile, 0.1% formic acid
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Agilent 6520 QTOF
MS:INSTRUMENT_TYPE               	QTOF
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	LC-MS data were processed with MassHunter Profinder version B.08.00 and Mass
MS:MS_COMMENTS                   	Profiler Professional version B.14.9.01 (Agilent Technologies) to identify
MS:MS_COMMENTS                   	differentiating molecular features (MFs; metabolites defined by a retention time
MS:MS_COMMENTS                   	and accurate mass) between PTLDS and non-PTLDS patients at baseline,
MS:MS_COMMENTS                   	post-treatment and one-year follow-up in cohort-one. The biosignature-MFs
MS:MS_COMMENTS                   	determined using cohort-one were targeted in patient samples from cohort-two
MS:MS_COMMENTS                   	using MassHunter Profinder.
MS:CAPILLARY_VOLTAGE             	4000
MS:DRY_GAS_FLOW                  	10 l/min
MS:DRY_GAS_TEMP                  	310
MS:FRAGMENT_VOLTAGE              	120
MS:NEBULIZER                     	45 psi
MS:OCTPOLE_VOLTAGE               	750 V
MS:MS_RESULTS_FILE               	ST001391_AN002320_Results.txt	UNITS:counts	Has m/z:Neutral masses	Has RT:Yes	RT units:Minutes
#END